Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Oral 💊 is the game changer !!!

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jan 25, 2021 9:15pm

76 Views

Post# 32382344

RE:RE:RE:RE:Oral 💊 is the game changer !!!

So where is the Oral exploratory preclinical study taking place if its not in Maryland ???

Padina wrote: Jlane,
well your position about my understanding is very wrong. USAMRIID does not have oral as part of its testing. The oral is still in early exploratory stage. USAMRIIDs job is to validate the formulation. Vaxil on the other hand will determine the best dosage form for its formulation whther oral solid dosage form or injectable. This is my field. I find it funny telling me i dont know d difference. Well any thing goes on a message board.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments